Curtana Pharmaceuticals is a clinical‑stage biotech developing an oral, CNS‑penetrant small‑molecule inhibitor, CT‑179, that targets the OLIG2 transcription factor to eradicate cancer stem cells and reverse tumor‑driven immune suppression in adult and pediatric brain cancers. By dismantling the cellular engine of recurrence, the therapy aims to improve outcomes for patients with recurrent glioblastoma and other aggressive central nervous system malignancies where current treatments are limited.
Funding
$52.3K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Standard treatments for adult and pediatric brain tumors often leave behind cancer stem cells that drive recurrence and suppress immune responses, resulting in poor survival rates for aggressive CNS malignancies such as recurrent glioblastoma and MGMT‑unmethylated GBM.
Solution
Curtana Pharmaceuticals is developing CT‑179, an orally administered, CNS‑penetrant small‑molecule that selectively inhibits the OLIG2 transcription factor, a key regulator of cancer stem cells in brain tumors. By blocking OLIG2, CT‑179 aims to eradicate the stem‑cell population that rebuilds tumor architecture and to reverse tumor‑induced immune suppression. The dual‑action approach is intended to prevent disease recurrence and enhance the efficacy of radiation, chemotherapy, and immunotherapy when used in combination. CT‑179 is being evaluated in a first‑in‑human Phase 1 OPAL trial for recurrent glioblastoma, with plans to expand into newly diagnosed MGMT‑unmethylated GBM and pediatric high‑grade gliomas.
Target Audience
Primary customers are neuro‑oncology clinical trial programs and healthcare providers treating patients with recurrent glioblastoma, MGMT‑unmethylated GBM, and high‑grade pediatric brain tumors.
Features
- Oral, blood‑brain barrier‑crossing small‑molecule inhibitor of OLIG2 transcription factor
- Targets cancer stem cells to disrupt tumor regeneration and reduce immune evasion
- Demonstrated preclinical synergy with radiation, EGFR inhibitors, and anti‑PD‑L1 therapies
- Designed for combination regimens across adult and pediatric CNS malignancies
- Supports both monotherapy and rational combination strategies in clinical development